LogicBio Therapeutics
Gene Therapy for Genetic and Infectious Diseases
Company Overview
Snapshot
Founded in January 2016 by Adi Barzel and Mark Kay, LogicBio Therapeutics operated with 11–50 employees. The company raised a total of $119 million across 3 funding rounds from 5 investors. In October 2018, LogicBio Therapeutics completed an Initial Public Offering on NASDAQ.
Business overview
LogicBio Therapeutics is a Health Tech & Life Sciences company focused on developing gene therapy vectors for previously incurable genetic and infectious diseases, including hemophilia, HIV/AIDS, and methylmalonic acidemia. The company's core technology utilizes a proprietary nonpathogenic adeno-associated viral vector, designed to offer improved efficiency and safety for treating both pediatric and adult patients. Operating within the Pharmaceuticals sector, LogicBio Therapeutics serves the North American market.
Strategic signal
In February 2019, LogicBio Therapeutics delisted from NASDAQ and ceased operations. This event signals a significant and challenging outcome for the company, indicating a failure to sustain its business model or achieve its strategic objectives, despite prior public market entry.
Company Intelligence Q&A
- When was LogicBio Therapeutics founded?
- LogicBio Therapeutics was founded in January 2016.
- Who are the founders of LogicBio Therapeutics?
- The founders of LogicBio Therapeutics are Adi Barzel and Mark Kay.
- What was a significant financial event for LogicBio Therapeutics in October 2018?
- In October 2018, LogicBio Therapeutics completed an Initial Public Offering on NASDAQ, raising $70 million.
- What was the outcome for LogicBio Therapeutics in February 2019?
- In February 2019, LogicBio Therapeutics delisted from NASDAQ and ceased to operate.
- Which investors participated in LogicBio Therapeutics' June 2017 funding round?
- In June 2017, LogicBio Therapeutics received funding from SBI JI Innovation Fund and Pontifax.